Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m
Change To Partnership Comes After First Positive Pivotal Data For Blood Disorders
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.
